Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease
Wei‐Ying Jen, Hagop M. Kantarjian, Tapan M. Kadia, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 1, pp. 30-47
Open Access | Times Cited: 17

Showing 17 citing articles:

Menin Inhibitors: New Targeted Therapies for Specific Genetic Subtypes of Difficult-to-Treat Acute Leukemias
Pasquale Niscola, Valentina Gianfelici, Marco Giovannini, et al.
Cancers (2025) Vol. 17, Iss. 1, pp. 142-142
Open Access
Cellular Epigenetic Targets and Epidrugs in Breast Cancer Therapy: Mechanisms, Challenges, and Future Perspectives
Ibrahim S. Alalhareth, Saleh M. Alyami, Abdulrhman Alshareef, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 207-207
Open Access
The Diagnostic Spectrum of Myelodysplastic Syndromes and Acute Myeloid Leukemia
Daniel A. Arber, Attilio Orazi
Advances in Anatomic Pathology (2025)
Closed Access
SOHO State of the Art Updates and Next Questions Acute Myeloid Leukemia: Current Status and Next Questions
Vishrut Shah, Farhad Ravandi
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
Treatment of Relapsed/Refractory AML—Novel Treatment Options Including Immunotherapy
Catherine Gutierrez, Anthony S. Stein, Amir T. Fathi, et al.
American Journal of Hematology (2025) Vol. 100, Iss. S2, pp. 23-37
Closed Access
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia
Courtney D. DiNardo, Wei‐Ying Jen, Koichi Takahashi, et al.
Leukemia (2025)
Closed Access
piRNAs in leukemogenesis: Mechanisms, biomarkers, and therapeutic implications
Gaurav Gupta, Muhammad Afzal, Ahsas Goyal, et al.
Clinica Chimica Acta (2025), pp. 120220-120220
Closed Access
Structurally diverse sesquiterpenes with anti-leukemia activity from the rare medicinal plant Liriodendron chinense
Yu‐Hang He, Hong Xiang, Zi‐Jie Long, et al.
Bioorganic Chemistry (2025) Vol. 158, pp. 108341-108341
Closed Access
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations
Warren Fiskus, Christopher P. Mill, Jessica Piel, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
The first-in-Africa ex vivo drug sensitivity testing platform identifies novel drug combinations for South African leukaemia patient cohort
Vanelle Larissa Kenmogne, Mutsa M. Takundwa, Ekene Emmanuel Nweke, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Drug Sensitivity patterns across FAB subtypes and molecular mutations in AML: A comprehensive analysis for precision medicine
Mohan Krishna Shrestha, Bishwas Mandal, Vishal Mandal, et al.
Clinical and Translational Discovery (2025) Vol. 5, Iss. 2
Open Access
Oral decitabine in acute myeloid leukemia: assessing efficacy, safety, and future implications for older patients
Pasquale Niscola
Expert Review of Hematology (2025)
Closed Access
Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies
Pasquale Niscola, Valentina Gianfelici, Gianfranco Catalano, et al.
Current Oncology (2024) Vol. 31, Iss. 11, pp. 6632-6658
Open Access | Times Cited: 1
Design and Development of a Series of 4-(piperazin-1-yl)pyrimidines as Irreversible Menin Inhibitors
Menglan Luo, Yunfei Ye, L. Tang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 280, pp. 116918-116918
Closed Access
Strategies for the treatment of acute myeloid leukemia with FLT3 mutations: a patent review
Lukáš Górecki, Eva Řezníčková, Vladimı́r Kryštof, et al.
Expert Opinion on Therapeutic Patents (2024), pp. 1-28
Closed Access
Latest Insights and Progress in the Clinical Management of Elderly Patients with Acute Myeloid Leukemia: From Genetic Advancements to Targeted Treatments
Pasquale Niscola, Nélida I. Noguera, Valentina Gianfelici, et al.
(2024)
Open Access
Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell lines
Erdal Toprak, Fatma N. Kalkan, Mustafa Yıldız, et al.
Research Square (Research Square) (2024)
Open Access
Recent progress in AML with recurrent genetic abnormalities
Yuichi Ishikawa
International Journal of Hematology (2024)
Closed Access
Page 1

Scroll to top